Benzinga Why Telomir Pharmaceuticals Stock Ran Up 35% On Wednesday Night
Telomir Pharmaceuticals' shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases. read more
Telomir Pharmaceuticals' shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases. read more